Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis-Reference-Cited by-同舟云学术

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis

Published:2019-11-24 Issue:1 Volume:11 Page:191-197
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Wang Hanping¹^ORCID,Guo Xiaoxiao²^ORCID,Zhou Jiaxin³,Li Yue⁴,Duan Lian⁵,Si Xiaoyan¹^ORCID,Zhang Li⁶,Liu Xiaowei⁷,Wang Mengzhao¹,Shi Juhong¹,Zhang Li¹

Affiliation:

1. Department of Respiratory MedicinePeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing China

2. Department of CardiologyPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing China

3. Department of Rheumatism and ImmunologyPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing China

4. Department of Digestive MedicinePeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing China

5. Department of EndocrinologyPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing China

6. Department of Clinical LaboratoryPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing China

7. Department of OphthalmologyPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13240

Reference21 articles.

1. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

2. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

3. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer

5. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors;World Journal of Clinical Oncology;2024-08-24

2. Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches;Cell Biochemistry and Biophysics;2024-07-02

3. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis;The Oncologist;2024-06-17

4. Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival;Respiratory Medicine;2024-06

5. A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis;Medicine;2024-04-19